Theriva Biologics, Inc.
Data quality: 83%
TOVX
NYSE
Manufacturing
Chemicals
$0.24
▼
$0.06
(-19.19%)
Mkt Cap: 11.01 M
Price
$0.24
Mkt Cap
11.01 M
Day Range
$0.24 — $0.28
52-Week Range
$0.16 — $1.50
Volume
4,767,400
Open $0.28
50D / 200D Avg
$0.20
23.08% above
50D / 200D Avg
$0.31
23.69% below
Quick Summary
Key Takeaways
Negative free cash flow of -16.70 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-273.48%
Below sector avg (-53.41%)
ROIC-87.82%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio0.90
Interest Coverage-394.28
Valuation
PE (TTM)
-0.46
Above sector avg (-1.48)
P/B Ratio1.63
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.5 | -1.5 |
| P/B | 1.6 | 1.6 |
| ROE % | -273.5 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -23.74 M |
| ROE | -273.48% | ROA | -71.22% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -16.70 M |
| ROIC | -87.82% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.90 |
| Interest Coverage | -394.28 | Asset Turnover | N/A |
| Working Capital | -1.10 M | Tangible Book Value | -12.88 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.46 | Forward P/E | N/A |
| P/B Ratio | 1.63 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -151.66% | ||
| Market Cap | 11.01 M | Enterprise Value | 3.49 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.08 | Revenue / Share | N/A |
| FCF / Share | -0.36 | OCF / Share | -0.36 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 70.37% |
| SBC-Adj. FCF | -17.38 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -23.74 M | -25.65 M | -18.35 M | -19.69 M | -14.27 M |
| EPS (Diluted) | -2.08 | -19.03 | -1.14 | -1.31 | -0.19 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -24.05 M | -26.35 M | -21.43 M | -21.58 M | -14.27 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 8.60 M | 12.03 M | 14.31 M | 11.72 M | 7.80 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 108,000.0 | 137,000.0 | 135,000.0 | 85,000.0 | 87,000.0 |
| Interest Expense | 61,000.0 | — | — | — | — |
| Income Tax | — | 0.0 | -1.64 M | -1.43 M | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 38.24 M | 35.35 M | 55.22 M | 71.86 M | 70.37 M |
| Total Liabilities | 22.86 M | 16.29 M | 15.52 M | 17.30 M | 4.96 M |
| Shareholders' Equity | 15.38 M | 19.07 M | 36.96 M | 56.39 M | 65.41 M |
| Total Debt | 1.67 M | 92,000.0 | 225,000.0 | 278,000.0 | — |
| Cash & Equivalents | 13.06 M | 11.61 M | 23.18 M | 41.79 M | 67.33 M |
| Current Assets | 17.47 M | 16.28 M | 27.40 M | 45.52 M | 68.86 M |
| Current Liabilities | 10.01 M | 7.59 M | 6.74 M | 7.06 M | 3.55 M |
{"event":"ticker_viewed","properties":{"ticker":"TOVX","listing_kind":"stock","pathname":"/stocks/tovx","exchange":"NYSE","country":"US"}}